Gilead Sciences/Pharmasset
On November 21, 2011, Gilead Sciences, Inc. (Nasdaq: GILD) and Pharmasset, Inc. (Nasdaq: VRUS) signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash. The transaction, which values Pharmasset at approximately $11 billion, was unanimously approved by Pharmasset’s Board of Directors. Gilead plans to finance the transaction with cash on hand, bank debt and senior unsecured notes. The company expects the transaction, when completed, to be dilutive to Gilead’s earnings through 2014 and accretive in 2015 and beyond.
Further guidance will be provided when the transaction closes, which is expected to be in Q112.
Under the terms of the merger agreement, a wholly-owned subsidiary of Gilead will promptly commence a tender offer to acquire all of the outstanding shares of Pharmasset’s common stock at a price of $137 per share in cash. Following successful completion of the tender offer, Gilead will acquire all remaining shares not tendered in the offer through a second step merger at the same price as in the tender offer.
The consummation of the tender offer is subject to various conditions, including a minimum tender of at least a majority of outstanding Pharmasset shares on a fully diluted basis, the expiration or termination of the waiting period under the Hart Scott Rodino Antitrust Improvements Act, and other customary conditions. The tender offer is not subject to a financing condition.
The $137 per share price in the transaction represents an 89% premium to Pharmasset’s closing share price on Friday, November 18, 2011, the last trading day prior to announcement, and 59% to Pharmasset’s all time high closing stock price.
Gilead has received commitments from Bank of America Merrill Lynch and Barclays Capital in connection with financing of the transaction.
Barclays Capital and Bank of America Merrill Lynch are acting as financial advisors to Gilead in the transaction. Morgan Stanley & Co. LLC is acting as the financial advisor to Pharmasset. Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal counsel to Gilead and Sullivan & Cromwell LLP is serving as legal counsel to Pharmasset.
Further guidance will be provided when the transaction closes, which is expected to be in Q112.
Under the terms of the merger agreement, a wholly-owned subsidiary of Gilead will promptly commence a tender offer to acquire all of the outstanding shares of Pharmasset’s common stock at a price of $137 per share in cash. Following successful completion of the tender offer, Gilead will acquire all remaining shares not tendered in the offer through a second step merger at the same price as in the tender offer.
The consummation of the tender offer is subject to various conditions, including a minimum tender of at least a majority of outstanding Pharmasset shares on a fully diluted basis, the expiration or termination of the waiting period under the Hart Scott Rodino Antitrust Improvements Act, and other customary conditions. The tender offer is not subject to a financing condition.
The $137 per share price in the transaction represents an 89% premium to Pharmasset’s closing share price on Friday, November 18, 2011, the last trading day prior to announcement, and 59% to Pharmasset’s all time high closing stock price.
Gilead has received commitments from Bank of America Merrill Lynch and Barclays Capital in connection with financing of the transaction.
Barclays Capital and Bank of America Merrill Lynch are acting as financial advisors to Gilead in the transaction. Morgan Stanley & Co. LLC is acting as the financial advisor to Pharmasset. Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal counsel to Gilead and Sullivan & Cromwell LLP is serving as legal counsel to Pharmasset.
View Older Stories
-
Antios Therapeutics Appoints Patrick T. Higgins to Board of Directors
-
Terns Appoints Three New Independent Directors to its Board
-
Noveome Biotherapeutics, Inc. Announces New Appointments to its Board of Directors
-
Gilead (GILD) Locks Trodelvy with $21B Immunomedics (IMMU) Deal as Some Question High Price Tag
-
Passage Bio Expands Executive Management Team
-
Passage Bio Expands Executive Management Team
-
Matinas BioPharma to Ring NYSE Opening Bell® on May 6, 2019
-
Matinas BioPharma to Ring NYSE Opening Bell® on May 6, 2019
-
Healthcare Payments Innovator MAPay Tackles Inefficiencies in Global Healthcare Transactions
-
Merck loses bid to revive $200 million Gilead verdict at U.S. high court
-
Antios Therapeutics Raises $25 Million in Oversubscribed Series A Financing to Pursue Hepatitis B Cure
-
Roivant Announces Creation of Roivant Pharma and Roivant Health and Launch of Altavant
-
Fish & Richardson Wins Federal Circuit Affirmance of Reversal of $200 Million Damages Against Gilead After Merck's "Unclean Hands"
-
Florida man gets prison for trading on tip about Gilead deal
-
Baird 'Incrementally Negative' on Gilead Sciences (GILD) Deal for Kite
-
2017 Community Awards Honor Academic and Industry Leaders, Georgia Power, UGA Research Center
-
Gabelli & Company Highlights 6 Potential Gilead Sciences (GILD) Takeover Targets
-
Baruch S. Blumberg Institute Congratulates Michael J. Sofia on Receiving 2016 Lasker-DeBakey Clinical Medical Research Award
-
Fish & Richardson Obtains Reversal of $200 Million Patent Verdict Against Gilead After Merck's "Pervasive Pattern of Misconduct"
-
Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute
-
Gilead shares look cheap but investors fret over growth
-
Gilead (GILD) Shares Weaken Following Release of Senate Finance Committee Investigation Into Pricing and Marketing of Sovaldi
-
Baruch S. Blumberg Institute Honors Six Scientists for Life-Saving Research
-
Pacific trade deal adds to U.S. price quandary for biotech drugs
-
Tekmira Pharma (TKMR) Plans Name Change to 'Arbutus Biopharma'
-
Tekmira Announces Launch of Arbutus Biopharma, a Hepatitis B Solutions Company
-
Tekmira Announces Launch of Arbutus Biopharma, a Hepatitis B Solutions Company
-
Gilead (GILD) Needs More Options in Hep B, Says RBC (TKMR) (ASMB)
-
ISS Recommends Shareholders Vote For Specialty Drug Pricing Risk Assessment Proposal At Gilead Sciences
-
Tekmira Announces Completion of the Merger With OnCore Creating a Leading Hepatitis B Solutions Company
-
Tekmira Pharma (TKMR), OnCore Biopharma Enter Merger Agreement
-
Tekmira Pharmaceuticals and OnCore Biopharma Announce Merger Agreement to Create Leading Global Hepatitis B Virus Company
-
OnCore Biopharma Agrees to Acquire Enantigen Therapeutics
-
OnCore Biopharma Licenses Second-Generation Cyclophilin Inhibitors From NeuroVive for the Treatment of Chronic HBV Infection
-
Notable 52-Week Highs and Lows of the Day 8/15: (ACHN) (GILD) (BITA) High; (BAA) (XIN) (EXXI) Low
-
Gilead Sciences (GILD) Receives Favorable Ruling in Arbitration with Roche (RHHBY)
-
Wyden and Grassley Seek Details on Solvaldi Pricing (GILD)
-
Nomura Securities Starts Gilead Sciences (GILD) at Buy; Top Biotech Stock Pick for 2014
-
Idenix Pharma (IDIX) Files Two New Patent Suits Against Gilead (GILD)
-
Bidding for Onyx Pharma (ONXX) Done? Not Likely...
-
Notable 52-Week Highs and Lows of the Day 01/10: (GILD) (IDIX) (CIE) High; (HMA) (WBMD) Low
-
Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD); 2012 Preview
-
Pre-Open Movers 12/16: (RRR) (ISTA) (ADBE) Higher; (STEM) (VRUS) (RIMM) Lower (more...)
-
Biotech M&A Will Be In Focus in 2012 - Goldman
-
Goldman Sachs Adds Gilead Sciences (GILD) to the Conviction Buy List on Acquisition Strategy
-
Shares of Gilead Sciences (GILD) Gain Back Majority of Acquisition Dip
-
UBS Maintains a 'Buy' on Gilead Sciences (GILD); Near Term Pain for Long Term Gain
-
Notable 52-Week Highs and Lows of the Day 11/21: (INHX) (SPPI) (GCA) High; (GILD) (RIMM) (NFLX) Low
-
Gilead (GILD) to Acquire Pharmasset (VRUS) in $11B Cash Deal
-
Gilead Sciences (GILD) to acquire Pharmasset (VRUS) for $137/share
